Posted in | News | Bionanotechnology

Aphios Receives U.S. Patent to Formulate Polymer Nanospheres

Aphios Corporation today announced that it was awarded United States Patent No. 7,708,915 B2 for “Polymer Microspheres/Nanospheres and Encapsulating Therapeutic Proteins Therein,” granted May 04, 2010.

This invention is an improved process to formulate polymeric microspheres and nanospheres, and encapsulate therapeutic proteins or other useful substances, and a polymer microspheres/nanospheres apparatus. This invention also entails methods of purifying protein-containing polymeric microspheres/nanospheres from unused polymer and an apparatus therefore.

“Polymer Microspheres/Nanospheres and Encapsulating Therapeutic Proteins Therein." Conventional large-scale production of polymeric microspheres utilizing numerous processing steps and large quantities of organic solvents is very time consuming, costly and inefficient. In addition, the exposure of therapeutic agents to organic solvent adversely effects protein integrity and bioactivity. The uniformity and integrity as well as processing time and the cost associated with preparation of biodegradable polymer microspheres containing therapeutic products are greatly reduced by using supercritical fluids, critical or near-critical fluids with or without polar cosolvents [SuperFluids™].

In our process, a biodegradable polymer such as PLGA is dissolved in SuperFluids™ and mixed with the target therapeutic in solution or as a slurry of nanoparticles at operating pressures. The mixture is then decompressed through a nozzle into an aqueous solution, liquid nitrogen or an empty vessel (spray dryer). Polymer nanospheres are formed encapsulating the protein therapeutics. Alternatively, the polymer-enriched SuperFluids™ stream can be decompressed into an aqueous solution containing the target therapeutic agent. In addition to reduction or elimination of organic solvent usage, use of SuperFluids™ for making nanospheres imparts advantages of no residual toxic organic solvent and pathogen safety.

SuperFluids™ polymer nanospheres (PNS) process can be utilized to encapsulate therapeutic proteins and other molecules without utilizing organic solvents as is traditionally done. By changing nozzle design and process parameters, the process can also be utilized to manufacture polymer microspheres. SuperFluids™ PNS is a single-step process that is readily scalable. SuperFluids™ PNS can be utilized for improving the oral bioavailability of peptides and proteins, depot delivery of peptides and proteins for sustained, controlled release and the subcutaneous and/or oral delivery of sensitive vaccine antigens.

Source: http://www.aphios.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Aphios Corporation. (2019, March 19). Aphios Receives U.S. Patent to Formulate Polymer Nanospheres. AZoNano. Retrieved on October 31, 2024 from https://www.azonano.com/news.aspx?newsID=18208.

  • MLA

    Aphios Corporation. "Aphios Receives U.S. Patent to Formulate Polymer Nanospheres". AZoNano. 31 October 2024. <https://www.azonano.com/news.aspx?newsID=18208>.

  • Chicago

    Aphios Corporation. "Aphios Receives U.S. Patent to Formulate Polymer Nanospheres". AZoNano. https://www.azonano.com/news.aspx?newsID=18208. (accessed October 31, 2024).

  • Harvard

    Aphios Corporation. 2019. Aphios Receives U.S. Patent to Formulate Polymer Nanospheres. AZoNano, viewed 31 October 2024, https://www.azonano.com/news.aspx?newsID=18208.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.